Company Development
May 23 2022

AND017 Cancer Related Anemia (CRA) - Phase II study NMPA IND approval

Nov 19 2021

AND019-Phase I study  NMPA IND approval

Oct 1 2021

AND019 – Phase I study FDA IND approval

Jul 2021

AND017 – Phase II study China central IRB approval

Jan 14 2021

AND017 – Phase II study FDA IND approval

Aug 2020

AND017 – China Phase I study complete

Aug 2020

Ground broken on a 200,000 square foot administrative office space and manufacturing facility in Hangzhou

Feb 2020

AND017 – Australia Phase I study complete

Nov 2019

"Innovative Entrepreneurship Team of Zhejiang Province" award

Oct 2019

Nobel Prize of Physiology or Med awarded to the MoA of AND017

May 2019

AND019 – Initiation of IND enabling study

Apr 2019

AND017 – China Phase I study IND approval

Jul 2018

12.5 million non-dilutive grant awarded by Yuhang Industrial Fund

Nov 2017

AND017 – Patent filed in China


R&D Initiation

July 15, 2014

Founded at Yuhang District, Hangzhou